Fibrocell Science Inc. (NASDAQ: FCSC) has commenced the recruitment of patients for the Phase 1/2 clinical study of its drug candidate known as FCX-007. The drug is being developed as a treatment for a devastating condition called recessive dystrophic epidermolysis bullosa (RDEB).
FCSC is recruiting adult patients for the study. However, it was not immediately clear how many patients it is targeting.
Fibrocell Science Inc. (NASDAQ: FCSC)’s FCX-007 is a genetically-modified drug compound. The company is developing the drug in collaboration with its partner Intrexon Corp (NYSE: XOM). It is worth pointing out that FCX-007 is the first genetically-modified drug compound in Fibrocell’s pipeline.
Although Fibrocell is only in the early stages of developing FCX-007 into a marketable product, the management believes that coming to the point of enrolling patients for the Phase 1/2 clinical trial is already a significant milestone. According to the company’s CEO, David Pernock, the Phase 1/2 study of FCX-007 is a meaningful step in the development of a treatment to tackle RDEB, which he describes as a disease with high mortality rate.
Sharply focused attention
Fibrocell Science Inc. (NASDAQ: FCSC) is hoping to give its all to the development of FCX-007 as it embarks on the important Phase 1/2 trial. After it discontinued work its non-genetically modified drug for vocal cord scarring, Fibrocell can now be laser focused on the FCX-007 program. The discontinuation of the non-genetically modified program has also freed up resources that FCSC will now tap to accelerate the development of FCX-007.
Other candidate for Fibrocell Science Inc. (NASDAQ: FCSC)
Besides the lead program FCX-007, Fibrocell has another genetically-modified drug candidate called FCX-013, which is being developed for the treatment of linear scleroderma and other indications.
Fibrocell Science Inc. (NASDAQ: FCSC)’s efforts are being noticed on Wall Street with analysts beginning to predict a bright future for the company. Analysts at Roth Capital have a BUY rating and $7 price target on the stock.